IN2012DE00594A - - Google Patents

Download PDF

Info

Publication number
IN2012DE00594A
IN2012DE00594A IN594DE2012A IN2012DE00594A IN 2012DE00594 A IN2012DE00594 A IN 2012DE00594A IN 594DE2012 A IN594DE2012 A IN 594DE2012A IN 2012DE00594 A IN2012DE00594 A IN 2012DE00594A
Authority
IN
India
Application number
Inventor
Raj Kamal Tripathi
Balawant Kumar
Ravishankar Ramachandran
Jitendra Kumar Tripathi
Smriti Bhaduria
Jimut Kanti Ghosh
Original Assignee
Council Scient Ind Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Council Scient Ind Res filed Critical Council Scient Ind Res
Priority to IN594DE2012 priority Critical patent/IN2012DE00594A/en
Publication of IN2012DE00594A publication Critical patent/IN2012DE00594A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2/00Peptides of undefined number of amino acids; Derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/18Testing for antimicrobial activity of a material
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5041Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving analysis of members of signalling pathways
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983Viruses
    • G01N33/56988AIDS or HTLV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse Transcribing RNA Viruses
    • C12N2740/00011Reverse Transcribing RNA Viruses
    • C12N2740/10011Retroviridae
    • C12N2740/16011Human Immunodeficiency Virus, HIV
    • C12N2740/16311Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value
    • G01N2500/10Screening for compounds of potential therapeutic value involving cells
IN594DE2012 2012-03-02 2012-03-02 IN2012DE00594A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
IN594DE2012 IN2012DE00594A (en) 2012-03-02 2012-03-02

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN594DE2012 IN2012DE00594A (en) 2012-03-02 2012-03-02
PCT/IB2013/051641 WO2013128418A2 (en) 2012-03-02 2013-03-01 Peptide inhibitors as novel anti-hiv therapeutics
US14/382,428 US9327009B2 (en) 2012-03-02 2013-03-01 Peptide inhibitors as novel anti-HIV therapeutics

Publications (1)

Publication Number Publication Date
IN2012DE00594A true IN2012DE00594A (en) 2015-08-21

Family

ID=48326351

Family Applications (1)

Application Number Title Priority Date Filing Date
IN594DE2012 IN2012DE00594A (en) 2012-03-02 2012-03-02

Country Status (3)

Country Link
US (1) US9327009B2 (en)
IN (1) IN2012DE00594A (en)
WO (1) WO2013128418A2 (en)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6358511B1 (en) * 1998-05-04 2002-03-19 Mount Sinai School Of Medicine Of The City University Of New York Inhibitors of HIV infection
DE19820224A1 (en) * 1998-05-06 1999-12-09 Markus Schott Binding partners and methods for competitive inhibition of the binding between NEF protein and calmodulin, as well as agents and use in HIV diseases
WO2001024810A1 (en) * 1999-10-05 2001-04-12 Epimmune Inc. Inducing cellular immune responses to human immunodeficiency virus-1 using peptide and nucleic acid compositions
KR20070057273A (en) * 2000-02-04 2007-06-04 듀크 유니버시티 Human immunodeficiency virus vaccine
AU2003284597A1 (en) * 2002-11-22 2004-06-18 Takeda Pharmaceutical Company Limited Apoptosis-associated protein and use thereof

Also Published As

Publication number Publication date
US9327009B2 (en) 2016-05-03
US20150182581A1 (en) 2015-07-02
WO2013128418A2 (en) 2013-09-06
WO2013128418A3 (en) 2014-01-30

Similar Documents

Publication Publication Date Title
IN2012CH04110A (en)
CN102663591K1 (en)
IN2012DE00244A (en)
ECSDI12012015S (en)
IN2012CH00815A (en)
CL2012001431A1 (en)
ECSDI13012578S (en)
IN2012DE00238A (en)
ECSDI12011675S (en)
BR112014019115A2 (en)
ECSMU12012094U (en)
ECSDI13012594S (en)
ECSDI12012014S (en)
IN2012DE00306A (en)
IN2012DE00411A (en)
IN2012DE00265A (en)
IN2012DE00760A (en)
IN2012DE00780A (en)
ECSDI12012086S (en)
GB201216181D0 (en)
IN2012CH03865A (en)
IN2012DE00872A (en)
IN2012CH01666A (en)
ECSDI12012129S (en)
IN2012CH05298A (en)